A series of UiO-66
materials with different functional groups (−H,
−NH2, and −NO2) have been evaluated
for the adsorption and release of a common ocular drug such as brimonidine
tartrate. UiO-66 samples were synthesized under solvothermal conditions
and activated by solvent exchange with ethanol. Experimental results
suggest
that the incorporation of surface functionalities gives rise to the
development of structural defects (missing linker defects) but without
altering the basic topology of the UiO-66 framework. These defects
improve the adsorption performance of the parent metal–organic
framework (MOF), while the bulkier functionalities infer slower release
kinetics, with the associated benefits for prolonged delivery of brimonidine.
Among the evaluated MOFs, defective UiO-66-NO2 can be proposed
as the most promising candidate due to the combination of a larger
brimonidine volumetric uptake (680 mg/cm3), a prolonged
delivery (period of up to 25 days), a small particle size, and a larger
instability. Contrariwise, at high concentrations UiO-66-NO2 has higher toxicity toward human retinal pigment epithelium cells
(ARPE-19) compared to the pure and NH2-functionalized UiO-66.